Unique effects of wnt signaling on prostate cancer cells: Modulation of the androgen signaling pathway by interactions of the androgen receptor gene and protein with key components of the canonical wnt signaling pathway

Androgen Action in Prostate Cancer

Volumn , Issue , 2009, Pages 569-586

  Tanner, Matthew J ^b   Levina, Elina ^b   Shtutman, Michael ^b   Chen, Mengqian ^b   Ohouo, Patrice ^b   Buttyan, Ralph ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901094392     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69179-4_24     Document Type: Chapter

References (77)

1. Aaltomaa, S., V. Karja, P. Lipponen, T. Isotalo, J. P. Kankkunen, M. Talja, and R. Mokka. 2005. Reduced alpha-and beta-catenin expression predicts shortened survival in local prostate cancer. Anticancer Res 25(6C): 4707-12.
2. Aberle, H., A. Bauer, J. Stappert, A. Kispert, and R. Kemler. 1997. beta-Catenin is a target for the ubiquitin-proteasome pathway. Embo J 16(13): 3797-804.
3. Amir, A. L., M. Barua, N. C. McKnight, S. Cheng, X. Yuan, and S. P. Balk. 2003. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem 278(33): 30828-34.
4. Arce, L., N. N. Yokoyama, and M. L. Waterman. 2006. Diversity of LEF/TCF action in development and disease. Oncogene 25(57): 7492-504.
5. Bafico, A., G. Liu, A. Yaniv, A. Gazit, and S. A. Aaronson. 2001. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3(7): 683-6.
6. Bierie, B., M. Nozawa, J. P. Renou, J. M. Shillingford, F. Morgan, T. Oka, M. M. Taketo, R. D. Cardiff, K. Miyoshi, K. U. Wagner, G. W. Robinson, and L. Hennighausen. 2003. Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22(25): 3875-87.
7. Bruxvoort, K. J., H. M. Charbonneau, T. A. Giambernardi, J. C. Goolsby, C. N. Qian, C. R. Zylstra, D. R. Robinson, P. Roy-Burman, A. K. Shaw, B. D. Buckner-Berghuis, R. E. Sigler, J. H. Resau, R. Sullivan, W. Bushman, and B. O. Williams. 2007. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67(6): 2490-6.
8. Chen, G., N. Shukeir, A. Potti, K. Sircar, A. Aprikian, D. Goltzman, and S. A. Rabbani. 2004. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101(6): 1345-56.
9. Chesire, D. R., C. M. Ewing, W. R. Gage, and W. B. Isaacs. 2002. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21(17): 2679-94.
10. Chesire, D. R., and W. B. Isaacs. 2002. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 21(55): 8453-69.
11. Clevers, H. 2006. Wnt/beta-catenin signaling in development and disease. Cell 127(3): 469-80.
12. de la Taille, A., M. A. Rubin, M. W. Chen, F. Vacherot, S. G. de Medina, M. Burchardt, R. Buttyan, and D. Chopin. 2003. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 9(5): 1801-7.
13. Dhanasekaran, S. M., T. R. Barrette, D. Ghosh, R. Shah, S. Varambally, K. Kurachi, K. J. Pienta, M. A. Rubin, and A. M. Chinnaiyan. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849): 822-6.
14. Dong, J. T. 2006. Prevalent mutations in prostate cancer. J Cell Biochem 97(3): 433-47.
15. Gavert, N., and A. Ben-Ze'ev. 2007. beta-Catenin signaling in biological control and cancer. J Cell Biochem 102(4): 820-8.
16. Gerstein, A. V., T. A. Almeida, G. Zhao, E. Chess, M. Shih Ie, K. Buhler, K. Pienta, M. A. Rubin, R. Vessella, and N. Papadopoulos. 2002. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34(1): 9-16.
17. Gioeli, D., B. E. Black, V. Gordon, A. Spencer, C. T. Kesler, S. T. Eblen, B. M. Paschal, and M. J. Weber. 2006. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 20(3): 503-15.
18. Glinsky, G. V., A. B. Glinskii, A. J. Stephenson, R. M. Hoffman, and W. L. Gerald. 2004. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113(6): 913-23.
19. Gounari, F., S. Signoretti, R. Bronson, L. Klein, W. R. Sellers, J. Kum, A. Siermann, M. M. Taketo, H. von Boehmer, and K. Khazaie. 2002. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21(26): 4099-107.
20. Gregory, C. W., X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson. 2004. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279(8): 7119-30.
21. Grimes, C. A., and R. S. Jope. 2001. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65(4): 391-426.
22. Grossmann, M. E., H. Huang, and D. J. Tindall. 2001. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22): 1687-97.
23. Hall, C. L., A. Bafico, J. Dai, S. A. Aaronson, and E. T. Keller. 2005. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65(17): 7554-60.
24. Heemers, H. V., J. D. Debes, and D. J. Tindall. 2008. The role of the transcriptional coactivator p300 in prostate cancer progression. Adv Exp Med Biol 617535-40.
25. Heinlein, C. A., and C. Chang. 2002. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16(10): 2181-7.
26. Horvath, L. G., S. M. Henshall, C. S. Lee, J. G. Kench, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2005. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 113(3): 415-22.
27. Jaggi, M., S. L. Johansson, J. J. Baker, L. M. Smith, A. Galich, and K. C. Balaji. 2005. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol 23(6): 402-6.
28. Kawano, Y., and R. Kypta. 2003. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116(Pt 13): 2627-34.
29. Kim, J. H., B. Kim, L. Cai, H. J. Choi, K. A. Ohgi, C. Tran, C. Chen, C. H. Chung, O. Huber, D. W. Rose, C. L. Sawyers, M. G. Rosenfeld, and S. H. Baek. 2005. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434(7035): 921-6.
30. Kioussi, C., P. Briata, S. H. Baek, D. W. Rose, N. S. Hamblet, T. Herman, K. A. Ohgi, C. Lin, A. Gleiberman, J. Wang, V. Brault, P. Ruiz-Lozano, H. D. Nguyen, R. Kemler, C. K. Glass, A. Wynshaw-Boris, and M. G. Rosenfeld. 2002. Identification of a Wnt/Dvl/beta-Catenin ! Pitx2 pathway mediating cell-type-specific proliferation during development. Cell 111(5): 673-85.
31. Kockeritz, L., B. Doble, S. Patel, and J. R. Woodgett. 2006. Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 7(11): 1377-88.
32. Koh, S. S., H. Li, Y. H. Lee, R. B. Widelitz, C. M. Chuong, and M. R. Stallcup. 2002. Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators. J Biol Chem 277 (29): 26031-5.
33. Kouzmenko, A. P., K. Takeyama, S. Ito, T. Furutani, S. Sawatsubashi, A. Maki, E. Suzuki, Y. Kawasaki, T. Akiyama, T. Tabata, and S. Kato. 2004. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem 279(39): 40255-8.
34. Li, H., J. H. Kim, S. S. Koh, and M. R. Stallcup. 2004. Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem 279(6): 4212-20.
35. Liao, X., J. B. Thrasher, J. Holzbeierlein, S. Stanley, and B. Li. 2004. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145(6): 2941-9.
36. Liu, S., R. L. Vinall, C. Tepper, X. B. Shi, L. R. Xue, A. H. Ma, L. Y. Wang, L. D. Fitzgerald, Z. Wu, R. Gandour-Edwards, R. W. deVere White, and H. J. Kung. 2008. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 27(4): 499-505.
37. Liu, X. H., A. Kirschenbaum, S. Yao, G. Liu, S. A. Aaronson, and A. C. Levine. 2007. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res 67(12): 5747-53.
38. Lustig, B., and J. Behrens. 2003. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129(4): 199-221.
39. Malbon, C. C., and H. Y. Wang. 2006. Dishevelled: a mobile scaffold catalyzing development. Curr Top Dev Biol 72153-66.
40. Masiello, D., S. Y. Chen, Y. Xu, M. C. Verhoeven, E. Choi, A. N. Hollenberg, and S. P. Balk. 2004. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 18(10): 2388-401.
41. Mazor, M., Y. Kawano, H. Zhu, J. Waxman, and R. M. Kypta. 2004. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Onco-gene 23(47): 7882-92.
42. Miller, J. R. 2002. The Wnts. Genome Biol 3(1): 3001.1-3001.15.
43. Mohler, J. L. 2008. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 22(2): 357-72.
44. Mulholland, D. J., H. Cheng, K. Reid, P. S. Rennie, and C. C. Nelson. 2002. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277(20): 17933-43.
45. Mulholland, D. J., S. Dedhar, H. Wu, and C. C. Nelson. 2006. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25(3): 329-37.
46. Niehrs, C. 2006. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25(57): 7469-81.
47. Nusse, R., A. van Ooyen, D. Cox, Y. K. Fung, and H. Varmus. 1984. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307(5947): 131-6.
48. Nusslein-Volhard, C., and E. Wieschaus. 1980. Mutations affecting segment number and polarity in Drosophila. Nature 287(5785): 795-801.
49. Olson, L. E., J. Tollkuhn, C. Scafoglio, A. Krones, J. Zhang, K. A. Ohgi, W. Wu, M. M. Taketo, R. Kemler, R. Grosschedl, D. Rose, X. Li, and M. G. Rosenfeld. 2006. Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell 125(3): 593-605.
50. Ossipova, O., N. Bardeesy, R. A. DePinho, and J. B. Green. 2003. LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat Cell Biol 5(10): 889-94.
51. Pawlowski, J. E., J. R. Ertel, M. P. Allen, M. Xu, C. Butler, E. M. Wilson, and M. E. Wierman. 2002. Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 277(23): 20702-10.
52. Pearson, H. B., A. McCarthy, C. M. Collins, A. Ashworth, and A. R. Clarke. 2008. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res 68(7): 2223-32.
53. Placencio, V. R., A. R. Sharif-Afshar, X. Li, H. Huang, C. Uwamariya, E. G. Neilson, M. M. Shen, R. J. Matusik, S. W. Hayward, and N. A. Bhowmick. 2008. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res 68(12): 4709-18.
54. Roy, A. K., and B. Chatterjee. 1995. Androgen action. Crit Rev Eukaryot Gene Expr 5(2): 157-76.
55. Saha, B., A. Arase, S. S. Imam, D. Tsao-Wei, W. Y. Naritoku, S. Groshen, L. W. Jones, and S. A. Imam. 2008. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. Prostate 68(1): 78-84.
56. Salas, T. R., J. Kim, F. Vakar-Lopez, A. L. Sabichi, P. Troncoso, G. Jenster, A. Kikuchi, S. Y. Chen, L. Shemshedini, M. Suraokar, C. J. Logothetis, J. DiGiovanni, S. M. Lippman, and D. G. Menter. 2004. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279(18): 19191-200.
57. Song, L. N., and E. P. Gelmann. 2005. Interaction of beta-catenin and TIF2/GRIP1 in transcrip-tional activation by the androgen receptor. J Biol Chem 280(45): 37853-67.
58. Song, L. N., R. Herrell, S. Byers, S. Shah, E. M. Wilson, and E. P. Gelmann. 2003. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 23(5): 1674-87.
59. Stanbrough, M., G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66(5): 2815-25.
60. Takayama, S., I. Rogatsky, L. E. Schwarcz, and B. D. Darimont. 2006. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. J Biol Chem 281 (26): 17856-63.
61. Taneja, S. S., S. Ha, N. K. Swenson, H. Y. Huang, P. Lee, J. Melamed, E. Shapiro, M. J. Garabedian, and S. K. Logan. 2005. Cell-specific regulation of androgen receptor phosphory-lation in vivo. J Biol Chem 280(49): 40916-24.
62. Tetsu, O., and F. McCormick. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398(6726): 422-6.
63. Tomlins, S. A., M. A. Rubin, and A. M. Chinnaiyan. 2006. Integrative biology of prostate cancer progression. Annu Rev Pathol 1243-71.
64. Truica, C. I., S. Byers, and E. P. Gelmann. 2000. Beta-catenin affects androgen receptor transcrip-tional activity and ligand specificity. Cancer Res 60(17): 4709-13.
65. Varambally, S., J. Yu, B. Laxman, D. R. Rhodes, R. Mehra, S. A. Tomlins, R. B. Shah, U. Chandran, F. A. Monzon, M. J. Becich, J. T. Wei, K. J. Pienta, D. Ghosh, M. A. Rubin, and A. M. Chinnaiyan. 2005. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8(5): 393-406.
66. Voeller, H. J., C. I. Truica, and E. P. Gelmann. 1998. Beta-catenin mutations in human prostate cancer. Cancer Res 58(12): 2520-3.
67. Wang, L., H. K. Lin, Y. C. Hu, S. Xie, L. Yang, and C. Chang. 2004. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 279(31): 32444-52.
68. Whitaker, H. C., J. Girling, A. Y. Warren, H. Leung, I. G. Mills, and D. E. Neal. 2008. Alterations in beta-catenin expression and localization in prostate cancer. Prostate 68(11): 1196-205.
69. Widelitz, R. 2005. Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors 23(2): 111-6.
70. Wissmann, C., P. J. Wild, S. Kaiser, S. Roepcke, R. Stoehr, M. Woenckhaus, G. Kristiansen, J. C. Hsieh, F. Hofstaedter, A. Hartmann, R. Knuechel, A. Rosenthal, and C. Pilarsky. 2003. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201(2): 204-12.
71. Yang, F., X. Li, M. Sharma, C. Y. Sasaki, D. L. Longo, B. Lim, and Z. Sun. 2002. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277(13): 11336-44.
72. Yang, X., M. W. Chen, S. Terry, F. Vacherot, D. L. Bemis, J. Capodice, J. Kitajewski, A. de la Taille, M. C. Benson, Y. Guo, and R. Buttyan. 2006. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25(24): 3436-44.
73. Yardy, G. W., D. C. Bicknell, J. L. Wilding, S. Bartlett, Y. Liu, B. Winney, G. D. Turner, S. F. Brewster, and W. F. Bodmer. 2008. Mutations in the AXIN1 Gene in Advanced Prostate Cancer. Eur Urol.
74. Yi, F., and B. J. Merrill. 2007. Stem cells and TCF proteins: a role for beta-catenin-independent functions. Stem Cell Rev 3(1): 39-48.
75. Yost, C., M. Torres, J. R. Miller, E. Huang, D. Kimelman, and R. T. Moon. 1996. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10(12): 1443-54.
76. Yu, Y. P., D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, C. McDonald, R. Thomas, R. Dhir, S. Finkelstein, G. Michalopoulos, M. Becich, and J. H. Luo. 2004. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22(14): 2790-9.
77. Zhang, T., T. Otevrel, Z. Gao, Z. Gao, S. M. Ehrlich, J. Z. Fields, and B. M. Boman. 2001. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61(24): 8664-7.